A detailed history of Swiss National Bank transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Swiss National Bank holds 149,400 shares of SNDX stock, worth $2.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
149,400
Previous 150,600 0.8%
Holding current value
$2.51 Million
Previous $3.09 Million 6.99%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$17.93 - $24.81 $21,516 - $29,772
-1,200 Reduced 0.8%
149,400 $2.88 Million
Q1 2024

May 07, 2024

BUY
$19.71 - $24.57 $161,622 - $201,474
8,200 Added 5.76%
150,600 $3.58 Million
Q4 2023

Feb 06, 2024

BUY
$11.39 - $21.67 $243,746 - $463,738
21,400 Added 17.69%
142,400 $3.08 Million
Q3 2023

Nov 08, 2023

BUY
$14.52 - $21.77 $24,684 - $37,009
1,700 Added 1.42%
121,000 $1.76 Million
Q2 2023

Aug 09, 2023

BUY
$19.35 - $22.31 $69,660 - $80,316
3,600 Added 3.11%
119,300 $2.5 Million
Q1 2023

May 10, 2023

SELL
$20.66 - $28.98 $283,042 - $397,026
-13,700 Reduced 10.59%
115,700 $2.44 Million
Q4 2022

Feb 08, 2023

BUY
$20.64 - $26.24 $332,304 - $422,464
16,100 Added 14.21%
129,400 $3.29 Million
Q3 2022

Nov 09, 2022

BUY
$18.51 - $24.79 $149,931 - $200,799
8,100 Added 7.7%
113,300 $2.72 Million
Q2 2022

Aug 09, 2022

BUY
$13.64 - $19.48 $160,952 - $229,864
11,800 Added 12.63%
105,200 $2.02 Million
Q1 2022

May 09, 2022

BUY
$14.84 - $22.15 $120,204 - $179,415
8,100 Added 9.5%
93,400 $1.62 Million
Q3 2021

Nov 08, 2021

BUY
$13.87 - $19.8 $30,514 - $43,560
2,200 Added 2.65%
85,300 $1.63 Million
Q2 2021

Aug 06, 2021

BUY
$13.42 - $25.18 $120,780 - $226,620
9,000 Added 12.15%
83,100 $1.43 Million
Q1 2021

May 07, 2021

BUY
$19.28 - $24.59 $17,352 - $22,131
900 Added 1.23%
74,100 $1.66 Million
Q4 2020

Feb 05, 2021

BUY
$15.1 - $26.44 $1.11 Million - $1.94 Million
73,200 New
73,200 $1.63 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $950M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.